Psilocybin not checked

COMPASS Pathways · COMP360

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2/3 trial completes
Trials
6 active
11 in total · 4 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Treatment Resistant Depression, PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms, PTSD, Post Traumatic Stress Disorder, Major Depressive Disorder
Main trialPhase 3
“Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)”In the company’s words, NCT05711940 on ClinicalTrials.gov
Other names
COMP360

Other drugs for Treatment Resistant Depression

All 6 drugs for Treatment Resistant Depression

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 13 Nov 2025 Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
Phase 2/3Recruiting Nov 2028 Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Phase 2Active, not recruiting Sep 2025 A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
Phase 3Completed 28 May 2025 Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
Phase 2Completed 30 Jul 2021 The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
Phase 2Completed 14 Oct 2021 The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
Phase 2Completed 12 Feb 2024 The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Phase 2Completed 18 Nov 2024 Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study
Phase 2Authorised not given The impact of psilocybin on pain in fibromyalgia patients: a multicenter trial
Phase 2Authorised not given Regression of Atherosclerosis induced by liFe chAnging Experience with psiLocybin
Phase 2Authorised not given Psilocybin in treatment-resistant depression
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Psilocybin

Following is part of Solo: you see every change to Psilocybin the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in